4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis

Published: Thursday, October 13, 2022 at 8:05 am

Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of a first-in-class disease modifying osteoarthritis drug (DMOAD) for a curative treatment of osteoarthritis,

Full Coverage